Anaplastic Large Cell Lymphoma, ALK-Negative Recruiting Phase 2 Trials for Tislelizumab (DB14922)

Also known as: Anaplastic Large Cell Lymphoma, ALK-negative

IndicationStatusPhase
DBCOND0061449 (Anaplastic Large Cell Lymphoma, ALK-Negative)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03493451A Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- NeoplasmsTreatment